Drug intelligence / Profile preview

5-HT3 receptor antagonist + olanzapine + dexamethasone

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A triple antiemetic regimen consisting of a 5-HT3 receptor antagonist, olanzapine, and dexamethasone. This combination is used for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high or moderately emetogenic chemotherapy. The regimen works through multiple pathways: 5-HT3 receptor antagonists block serotonin receptors, olanzapine blocks multiple neurotransmitter receptors (dopamine, serotonin, adrenergic, and histamine), and dexamethasone provides anti-inflammatory effects.

Other names: 5HT3RA + olanzapine + dexamethasoneOlanzapine combined with 5-HT3 RA plus dexamethasone

Targets

HTR3A (5-hydroxytryptamine receptor 3A)GR (Glucocorticoid receptor)DRD2 (Dopamine D2 Receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on 5-HT3 receptor antagonist + olanzapine + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-HT3 receptor antagonist + olanzapine + dexamethasone.

Explore the full profile